Tagrisso causes complaints over issue biopsy

AstraZeneca Korea mentioned about the fact the Tagrisso’s(generic name: osimertinib) health insurance benefits will only be accepted only if a tissue biopsy is positive.

Tagrisso is a novel drug which overcame EGFR-targeted therapies’ resistance for the world’s first time in the non-small cell lung cancer treatment field; it can be used for patients with resistance to the primary treatment EGF...